In the article by Bonow et al, “ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease),” which appeared in the August 1, 2006, issue of the journal (Circulation. 2006;114:450–527), the following correction should be made. This error has been corrected in the current online version of the article.
On page 506, Section IX, Recommendation 6, “INR of 2.5 to 3.5” should be changed to “INR of 2.0 to 3.0” to read “After MV replacement with a bioprosthesis and risk factors, warfarin is indicated to achieve an INR of 2.0 to 3.0. (Level of Evidence: C).”